Edwards Lifesciences Corp (NYSE:EW)’s traded shares stood at 5.33 million during the latest session, with the company’s beta value hitting 1.08. At the last check today, the stock’s price was $78.62, to imply an increase of 3.72% or $2.82 in intraday trading. The EW share’s 52-week high remains $78.90, putting it -0.36% down since that peak but still an impressive 25.04% since price per share fell to its 52-week low of $58.93. The company has a valuation of $46.12B, with an average of 4.71 million shares in intraday trading volume over the past 10 days and average of 4.17 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Edwards Lifesciences Corp (EW), translating to a mean rating of 2.12. Of 17 analyst(s) looking at the stock, 1 analyst(s) give EW a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 14 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.58.
Edwards Lifesciences Corp (NYSE:EW) trade information
After registering a 3.72% upside in the latest session, Edwards Lifesciences Corp (EW) has traded red over the past five days. The 5-day price performance for the stock is 2.79%, and 2.15% over 30 days. With these gigs, the year-to-date price performance is -9.68%. Short interest in Edwards Lifesciences Corp (NYSE:EW) saw shorts transact 7.21 million shares and set a 1.8 days time to cover.
The extremes give us $75 and $90 for target low and target high price respectively. As such, EW has been trading -14.47% off suggested target high and 4.6% from its likely low.
Edwards Lifesciences Corp (EW) estimates and forecasts
The rating firms project that company’s revenue will grow 9.47% compared to the previous financial year.
Revenue forecast for the current quarter as set by 25 analysts is 1.49B. Meanwhile, for the current quarter, a total of 25 analyst(s) estimate revenue growth to 1.54B.Earnings reports from the last fiscal year show that sales brought in 1.35B and 1.39B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 9.86% before jumping 11.00% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -2.36% for the past 5-year period. While 2025 is set for a 2.48% return in earnings, projections for the next 5 years are at 8.82% annually.
EW Dividends
Edwards Lifesciences Corp has its next earnings report out on 2025-Apr-23. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Edwards Lifesciences Corp (NYSE:EW)’s Major holders
Edwards Lifesciences Corp insiders hold 0.91% of total outstanding shares, with institutional holders owning 89.18% of the shares at 90.00% float percentage. In total, 89.18% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 53.58 million shares (or 8.8982% of shares), all amounting to roughly $4.95 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 50.98 million shares, or about 8.4663% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.71 billion.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Edwards Lifesciences Corp (EW) shares. Going by data provided on Mar 31, 2025 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 18.63 shares. This is just over 3.18% of the total shares, with a market valuation of $1.48 billion. Data from the same date shows that the other fund manager holds a little less at 16.39, or 2.79% of the shares, all valued at about 1.3 billion.
